{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Flublok",
    "query": {
      "intervention": "Flublok"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Flublok&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T21:34:57.410Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03722589",
      "title": "Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Flublok",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flucelvax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High-Dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 944,
      "start_date": "2018-09-12",
      "completion_date": "2020-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-07-22",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Temple, Texas",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03722589"
    },
    {
      "nct_id": "NCT06518577",
      "title": "Immunogenicity of Influenza Vaccinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Flucelvax® (ccIIV3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flublok® (RIV3)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 606,
      "start_date": "2024-09-09",
      "completion_date": "2025-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06518577"
    },
    {
      "nct_id": "NCT05650554",
      "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5413",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Standard Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza High-Dose Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2022-12-12",
      "completion_date": "2024-04-02",
      "has_results": false,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 28,
      "location_summary": "Chula Vista, California • Gardena, California • Long Beach, California + 24 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05650554"
    },
    {
      "nct_id": "NCT02747407",
      "title": "Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Astrocytoma",
        "Glioma",
        "Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "Hepatitis A Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Tetanus Toxoid Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2016-05",
      "completion_date": "2021-09-09",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02747407"
    },
    {
      "nct_id": "NCT06015282",
      "title": "The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Investigational aQIVc",
          "type": "BIOLOGICAL"
        },
        {
          "name": "licensed QIVr",
          "type": "BIOLOGICAL"
        },
        {
          "name": "licensed aQIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 7741,
      "start_date": "2023-11-03",
      "completion_date": "2025-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 51,
      "location_summary": "Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06015282"
    },
    {
      "nct_id": "NCT03945825",
      "title": "Flublok or Fluzone With Advax-CpG55.2 or AF03",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "AF03",
          "type": "DRUG"
        },
        {
          "name": "Delta Inulin-CpG55.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Virus Quadrivalent Inactivated Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Seasonal Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 241,
      "start_date": "2019-06-10",
      "completion_date": "2020-09-18",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 8,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945825"
    },
    {
      "nct_id": "NCT02872311",
      "title": "Open-Label Influenza Vaccine Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immune Response"
      ],
      "interventions": [
        {
          "name": "High Dose Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adjuvanted Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Marshfield Clinic Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "65 Years to 74 Years"
      },
      "enrollment_count": 179,
      "start_date": "2016-09",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 1,
      "location_summary": "Marshfield, Wisconsin",
      "locations": [
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02872311"
    },
    {
      "nct_id": "NCT05513053",
      "title": "Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "9 Years to 49 Years"
      },
      "enrollment_count": 1308,
      "start_date": "2022-10-27",
      "completion_date": "2023-10-27",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05513053"
    },
    {
      "nct_id": "NCT05553301",
      "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5407",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Standard Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza High-Dose Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 560,
      "start_date": "2022-10-03",
      "completion_date": "2024-01-19",
      "has_results": false,
      "last_update_posted_date": "2025-01-24",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 23,
      "location_summary": "Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05553301"
    },
    {
      "nct_id": "NCT05624606",
      "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5410",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza vaccine RIV4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza Standard Dose QIV-SD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza High Dose QIV-HD",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2022-11-28",
      "completion_date": "2024-03-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-09-02T21:34:57.410Z",
      "location_count": 23,
      "location_summary": "Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05624606"
    }
  ]
}